Neuraxpharm Group, a European specialty pharmaceutical company focused on the central nervous system, has expanded its operations in Southern Europe with the launch of Neuraxpharm Portugal, it was reported yesterday.
The new office will be part of the company's Southern European Region that includes Italy, Spain and now Portugal.
Javier Mercade, general manager for Italy and Spain, was named as head of the Southern Region earlier this year, which will include Spain, Italy and Portugal. The company has also named Teng Dias as commercial director of the Portugal business.
GC Biopharma's GC1130A receives EMA Orphan Drug Designation
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Newron enrols 290 patients in schizophrenia study
Vistagen granted European patent for AV-101 to treat neuropathic pain
Alora Pharmaceuticals announces Relexxii commercial launch
IGC Pharma granted patent for Alzheimer's drug formulation
NRx Pharmaceuticals signs data agreement with Columbia University for IV Ketamine trials
Cambridge Cognition launches AQUA for automated quality assurance in CNS clinical trials
Shanghai Zhimeng Biopharma's CB03 receives US FDA orphan drug designation
Genentech's Alecensa demonstrates 76% reduction in disease recurrence risk
NRx Pharmaceuticals announces presentation at 8th Annual Dawson James Conference